Mainz

• Cangrelor safety and pharmacodynamics in paediatric subjects with congenital heart disease Pending
  2025-523109-14-00 5 Congenital Heart Disease
• A Phase 3 extension study to assess the long-term safety and efficacy of remibrutinib in adult participants with moderate to severe hidraden … Pending
  2025-523259-72-00 5 Hidradenitis Suppurativa (HS)
• A trial to learn how well AZD0120 works and how safe it is in people with relapsed or refractory multiple myeloma. Pending
  2025-523285-25-00 5 Relapsed or Refractory Multiple Myeloma
• Safety and Efficacy of VX-828/Deutivacaftor Combination Therapy With and Without Tezacaftor in Subjects With Cystic Fibrosis Pending
  2025-523400-72-00 4 Cystic fibrosis
• Symbiotic-GI-13, A Study to Learn About the Study Medicine Called PF-08634404 as Monotherapy and Combination Therapy in Adult Participants w … Pending
  2025-523525-17-00 9 Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma
• A clinical study to investigate the safety and tolerability of efimosfermin alfa injection in participants with known or suspected F2- or F3 … Pending
  2025-523674-16-00 5 Metabolic Dysfunction-Associated Steatohepatitis (MASH)
• A pivotal clinical study to investigate the safety and efficacy of efimosfermin alfa injection in participants with biopsyconfirmed F2- or F … Pending
  2025-523675-39-00 5 Metabolic Dysfunction-Associated Steatohepatitis (MASH)
• A study in people with advanced extrapulmonary neuroendocrine cancer to compare obrixtamig plus carboplatin and etoposide treatment with sta … Pending
  2025-523869-22-00 5 advanced or metastatic extrapulmonary neuroendocrine carcinoma
• A Study of Enpatoran in Cutaneous Manifestations of Lupus With or Without Systemic Disease Pending
  2025-523871-44-00 5 Cutaneous Manifestations of Lupus Erythematosus With or Without System
• Accelerate Improvement in Multiple Myeloma for Newly Diagnosed Transplant-Eligible Patients (AugMMent) Pending
  2025-523990-40-00 5 Newly diagnosed Multiple Myeloma in patients eligible for stem cell tr
• A study of BMS-986504 as Monotherapy and in Combination with Other Agents in Participants with Advanced and/or Metastatic Solid Tumors with … Pending
  2025-524285-18-00 4 Advanced and/or Metastatic Solid Tumors with Homozygous MTAP Deletion
• BETRI-Prospective: Asthma control in Single Inhaler ICS/LABA/LAMA (87/5/9 pMDI [BDP/FF/GB - 100/6/12.5 µg]) vs Single Inhaler ICS/LABA (200/ … Pending
  2025-524289-56-00 6 Asthma
• ALTERNATION Trial: A Clinical Trial Evaluating Everolimus-Based, Calcineurin Inhibitor-Free Immunosuppression One Year After Liver Transplan … Pending
  2025-524312-11-00 5 Patients after the first year following liver transplantation
• A Phase 3 Study of Orelabrutinib in Non-active Secondary Progressive Multiple Sclerosis Pending
  2025-524322-18-00 5 Non-active Secondary Progressive Multiple Sclerosis (SPMS)
• Real-world study to evaluate how effective and safe Pegcetacoplan is in patients with rare kidney diseases called C3G or IC-MPGN in multiple … Pending
  2025-524487-37-00 6 Primary Immune Complex Membranoproliferative Glomerulonephritis (IC-MP
• Bempedoic acid/ezetimibe/high-intensity statin in patients without cardiovascular events Pending
  2025-524625-41-00 5 Coronary atherosclerosis
• Epcoritamab in Relapsed/Refractory Marginalzone Lymphoma - A MULTICENTER OPEN LABEL SINGLE-ARM PHASE II STUDY (EPOS-1) Pending
  2025-524879-23-00 4 Marginal Zone Lymphoma
• A study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination with IV Bevacizumab Compared to Standard of Care IV Bevacizumab i … Recruiting
  2025-521712-19-00 5 2026-07-06 Colorectal Cancer
• A clinical trial of V940 with or without MK-3475A in people with non-small cell lung cancer (V940-014) Recruiting
  2025-522643-18-00 5 2026-06-16 Stage I NSCLC
• Study to assess how safe and effective is HRX215 in participants who underwent minor and major liver surgery due to colon carcinoma metastas … Recruiting
  2025-523630-59-00 9 2026-06-12 colon carcinoma metastases
• A Phase 3 Study of Orelabrutinib in Patients with Primary Progressive Multiple Sclerosis Recruiting
  2025-524316-11-00 5 2026-06-11 Primary Progressive Multiple Sclerosis (PPMS)
• Study of Volrustomig as Monotherapy or in Combination with Anti- cancer Agents in Participants with Advanced/Metastatic Solid Tumors Recruiting
  2025-523947-36-00 4 2026-06-10 Sub-study 5: Unresectable Pleural Mesothelioma (Volrustomig Monotherap
• PODOMOUNT-Basket, a study to test whether BI 764198 helps adults and adolescents with different types of kidney disease Recruiting
  2025-523425-17-00 4 2026-06-03 Proteinuric kidney diseases
• Long-term safety and efficacy evaluation of lunsekimig (SAR443765) in adult participants with moderate-to-severe asthma. Recruiting
  2025-522896-27-00 4 2026-05-11 Asthma

Showing 25–48 of 603 trials